ICON plc
ICON plc is a global provider of clinical, consulting, and commercial services, dedicated to helping pharmaceutical, biotechnology, and medical device companies bring new drugs and devices to market faster. The company offers a comprehensive range of services that span the entire lifecycle of product development, from early clinical phases to post-marketing. ICON is committed to delivering high-quality, harmonized data and innovative solutions to improve patient recruitment, retention, and engagement, while ensuring regulatory compliance and operational efficiency.
ICON plc
2100 Pennbrook Parkway, North Wales, PA 19454, USA
What We Do
ICON offers bespoke, seamless solutions to meet unique sponsor challenges, providing agile, adaptable outsourcing models that fit evolving needs in a dynamic clinical research landscape.
Ensuring the highest levels of safety and accuracy in clinical trials, ICON provides end-to-end cardiac safety solutions, including ECG, event monitoring, BPM, long-term Holter monitoring, ECHO, and MUGA studies.
Specializing in the planning, management, execution, and analysis of Phase 2-3 clinical trials, ICON provides a flexible approach to improve cycle times, constrain costs, and reduce risks.
ICON offers end-to-end services, operational models, and technology to deliver customized solutions for decentralized clinical trials, improving patient recruitment, retention, and diversity.
ICON specializes in early phase development services, enabling informed decision-making for drug development programs with a focus on clinical pharmacology and volunteer recruitment.
ICON provides flexible, agile, and proactive laboratory solutions dedicated to global clinical development, offering bioanalytical, central, and specialty laboratory services.
ICON offers integrated solutions based on the science of imaging biomarkers, improving decision-making, increasing efficiency, and potentially reducing trial costs.
Patient-centric clinical trial services that increase recruitment and retention by making it easier for sites and patients to participate in trials.
ICON provides customized FSP models to drive operational efficiencies and accelerate clinical development, offering a range of globally scalable solutions.
As the industry's largest life sciences language services provider, ICON delivers translations, linguistic validations, and market-dominant COA expertise.
ICON offers integrated solutions for market access, pricing, communications, and health economics to support brand success worldwide.
ICON provides in-depth scientific expertise across disciplines, enabling cost-effective and timely product and drug development programs.
ICON delivers operational and consulting services to achieve product authorisation, through the strategic design and delivery of real-world evidence studies and late phase research.
ICON's Internal Medicine and Immunology team provides guidance and insight from therapeutic and clinical experts, with experience spanning early-phase development through successful regulatory submission. They have conducted over 360 immunology studies, resulting in the approval of five important drugs.
ICON has extensive experience in cardiovascular clinical research trials, focusing on key indications such as heart failure, lipid disorders, diabetes, and rare diseases. They have conducted 118 studies involving 36,415 patients over the last five years.
ICON's Infectious Disease team applies proven strategies to clinical trials, minimizing risk and generating reliable data. They have conducted 432 studies with over 461,800 patients and volunteers worldwide.
ICON provides innovative processes for CNS clinical trials, including protocol design and real-time data quality analysis. They have conducted over 830 studies involving 150,900 patients.
ICON supports biosimilar development with deep expertise in drug development, clinical study design, and regulatory strategy. They have participated in over 45 biosimilar trials across 59 countries.
ICON accelerates rare disease drug development with expertise in patient recruitment and retention, having conducted 779 studies involving over 24,000 patients.
ICON's Women's Health team conducts trials across a broad range of indications, having conducted over 130 studies involving 45,000 patients in the last five years.
ICON is dedicated to pediatric clinical research, having contributed to the approval of 21 pediatric medicinal products through 421 studies involving 228,477 patients.
ICON provides tailored strategies for Cell and Gene Therapy studies, having conducted 171 studies involving 10,852 patients across 3,092 sites worldwide.
ICON has the experience and expertise to help sponsors overcome the challenges associated with obesity research and clinical trials, offering a comprehensive suite of integrated clinical development services for obesity trials.
ICON has led the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19, working with global biotech, pharma, government, and NGOs.
News & Updates
Using exclusive data from ICON’s 2023 survey with Citeline, this report presents valuable insights from 133 influential decision-makers within biotech and venture capital organisations from across North America, Europe, and Asia Pacific.
This whitepaper describes the rigorous, iterative linguistic validation process for COAs that ensures conceptual equivalency and cultural relevance for each required translation.
This whitepaper discusses the transition from paper to electronic versions of documents in clinical research to improve participant experience and data quality.
This whitepaper details the prerequisites for controlled use of Clinical Outcome Assessments (COAs) and suggestions for streamlining the licensing process.
This whitepaper describes the adoption of an eCOA solution and shares a recommended approach to planning and implementing eCOA to mitigate risks of delaying study start-up.
This whitepaper suggests a design overhaul for scientific posters to make a lasting impression during poster sessions.